Eli Lilly (LLY)Officer sold ~$723K

~$723K

Approx. value · 900 sh @ $803.38

5,480

Holds after · shares reported

Traded

Nov 8, 2024

Filed

Nov 8, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 13, 2024FDAFDA drug approval: Ebglyss
2. Sep 27, 2024FDAFDA drug approval: Retevmo
3. Sep 27, 2024FDAFDA drug approval: Retevmo
4. Sep 27, 2024FDAFDA drug approval: Retevmo
5. Sep 27, 2024FDAFDA drug approval: Retevmo
6. Oct 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
7. Oct 18, 2024FDAFDA drug approval: Zepbound
8. Oct 30, 2024CongressDisclosed purchase of LLY — reported range $15,001 - $50,000
9. Nov 8, 2024 · this disclosureInsiderOfficer sold ~$723K of LLY shares in the open market

What came next

1. Nov 8, 2024CongressDisclosed sale of LLY — reported range $15,001 - $50,000
2. Nov 13, 2024FDAFDA drug approval: Verzenio
3. Nov 14, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
4. Nov 19, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
5. Dec 9, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
6. Dec 10, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
7. Dec 11, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
8. Dec 12, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
9. Dec 13, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
10. Dec 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
11. Dec 18, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
12. Dec 20, 2024FDAFDA drug approval: Zepbound
13. Dec 24, 2024CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
14. Jan 8, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
15. Jan 15, 2025FDAFDA drug approval: Omvoh
16. Jan 15, 2025FDAFDA drug approval: Omvoh
17. Jan 21, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
18. Jan 22, 2025CongressDisclosed purchase of LLY — reported range $50,001 - $100,000
19. Jan 27, 2025FDAFDA drug approval: Cyramza
20. Feb 6, 2025Insider · 1 personInsiders: 22 sales (~$183.6M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Donald A Zakrowski, SVP, Finance, & CAO

• SEC Form 4 at Eli Lilly (LLY)Aug 11, 2026
• SEC Form 4 at Eli Lilly (LLY)Nov 13, 2025
• SEC Form 4 at Eli Lilly (LLY)Aug 28, 2025
• SEC Form 4 at Eli Lilly (LLY)May 27, 2025
• SEC Form 4 at Eli Lilly (LLY)Mar 13, 2025

The full history of Donald A Zakrowski, SVP, Finance, & CAO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Eli Lilly

• SEC Form 144Oct 7, 2026
• USAspending.gov award recordSep 1, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 18, 2026

Everything OQRO holds on this company is on its LLY page.